Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma

Sponsor
Sun Yat-sen University
Study ID
NCT05010434
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Sintilimab and Bevacizumab Combined with Radiotherapy — DRUG
    Before radiotherapy: Bevacizumab+Sintilizumab, Q3w, 2 cycles in total. Radiation therapy: 30-50Gy/10 fractions. After radiotherapy: Bevacizumab+Sintilizumab, Q3w until disease progression or toxicity is intolerable.

Study Details

The purpose of this study is to investigate both the efficacy and safety of sintilimab combined with bevacizumab and radiotherapy in advanced hepatocellular carcinoma.

Key Dates

First listed
Aug 18, 2021
Start date
Aug 16, 2021
Status verified
Sep 2023
Primary completion
Sep 30, 2023
Completion
Sep 30, 2023

Study Design

Enrollment
46 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Sintilimab and Bevacizumab Combined with Radiotherapy

Primary Outcome Measure

ORR (objective response rate) [ Time Frame: through study completion, up to 2 year ]

Related Studies